Eli Lilly and Company (NYSE:LLY) Stock Holdings Boosted by Thurston Springer Miller Herd & Titak Inc.

Thurston Springer Miller Herd & Titak Inc. increased its position in Eli Lilly and Company (NYSE:LLY) by 31.5% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 17,209 shares of the company’s stock after buying an additional 4,124 shares during the period. Eli Lilly and Company accounts for about 2.4% of Thurston Springer Miller Herd & Titak Inc.’s holdings, making the stock its 5th largest holding. Thurston Springer Miller Herd & Titak Inc.’s holdings in Eli Lilly and Company were worth $14,216,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Mascagni Wealth Management Inc. purchased a new position in Eli Lilly and Company in the fourth quarter valued at approximately $43,000. FPC Investment Advisory Inc. raised its position in Eli Lilly and Company by 358.3% in the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock valued at $45,000 after purchasing an additional 43 shares during the period. Prudent Man Investment Management Inc. purchased a new position in Eli Lilly and Company in the fourth quarter valued at about $48,000. Compass Financial Services Inc purchased a new position in Eli Lilly and Company in the fourth quarter valued at about $50,000. Finally, Capital A Wealth Management LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $63,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

LLY opened at $766.78 on Thursday. The company has a 50-day moving average of $772.75 and a 200-day moving average of $799.41. The company has a market capitalization of $726.71 billion, a P/E ratio of 65.48, a PEG ratio of 1.40 and a beta of 0.48. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The firm had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same period in the prior year, the firm earned $2.58 earnings per share. The firm’s quarterly revenue was up 45.2% compared to the same quarter last year. Equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.78%. The ex-dividend date is Friday, May 16th. Eli Lilly and Company’s dividend payout ratio (DPR) is 48.82%.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.13% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts recently commented on LLY shares. Hsbc Global Res downgraded Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a report on Monday, April 28th. Cantor Fitzgerald initiated coverage on shares of Eli Lilly and Company in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 price objective on the stock. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a “neutral” rating to a “buy” rating and dropped their price objective for the company from $892.00 to $888.00 in a research note on Tuesday, April 8th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,011.37.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.